AltruBio is focused on developing innovative therapeutics for immunological diseases, particularly through its lead product candidates, ALTB-168 and ALTB-268. Both are humanized therapeutic antibodies that target PSGL-1/CD162, functioning as immune checkpoint agonists. ALTB-168 has shown clinical efficacy in treating various T-cell mediated conditions, including psoriasis, psoriatic arthritis, ulcerative colitis, and acute graft versus host disease (GvHD). Its unique mechanism of action preferentially down-regulates late-stage, chronically activated T cells while preserving the function of resting and early-activated T cells, which helps maintain the body's immune defenses. This approach aims to provide durable clinical benefits with a reduced risk of adverse events, such as infections and cancer, which are often associated with traditional immunosuppressive therapies.

Building on the foundation of ALTB-168, AltruBio is advancing ALTB-268, a more potent second-generation candidate designed to enhance efficacy while maintaining safety profiles. The development of ALTB-268 is expected to further improve the down-regulation of chronic pathogenic T cells, potentially allowing for lower dosages to achieve similar therapeutic effects. AltruBio's pipeline reflects a commitment to addressing unmet medical needs in immunology, with ongoing clinical trials aimed at confirming the efficacy of these novel therapies in various inflammatory diseases. The company's innovative approach positions it to make significant contributions to the treatment landscape for patients suffering from autoimmune and immune-mediated conditions.

United States

AltruBio is developing first-in-class immunomodulators to target diseases of the immune system. Our world-class global team brings a breadth of expertise in immunology and drug development to bring our biologic treatments to patients.  

AltruBio

Company Details